Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

80.750
-0.200-0.25%
Volume:7.79M
Turnover:627.96M
Market Cap:138.97B
PE:-1.26K
High:81.300
Open:81.000
Low:79.600
Close:80.950
52wk High:109.100
52wk Low:28.650
Shares:1.72B
HK Float Shares:1.72B
Volume Ratio:0.69
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:2.65%
PB:8.72
PE(LYR):-1,256.56
PS:11.01

Loading ...

Why Innovent Biologics (SEHK:1801) Is Down 7.4% After Promising Adolescent Obesity Data For Mazdutide

Simply Wall St.
·
Dec 15

Hong Kong Stock Short Interest Data as of December 12

Stock News
·
Dec 12

Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity

Reuters
·
Dec 12

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1B Clinical Trial in Chinese Adolescents With Obesity

THOMSON REUTERS
·
Dec 12

Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside

Simply Wall St.
·
Dec 10

BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs

Stock News
·
Dec 10

Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares

Reuters
·
Dec 10

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of Ibi3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

THOMSON REUTERS
·
Dec 10

CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2

Stock News
·
Dec 09

Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis

Reuters
·
Dec 09

Innovent Announces Pecondle® (Picankibart Injection) Phase 3 Study (Clear-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

THOMSON REUTERS
·
Dec 09

HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market

Stock News
·
Dec 08

Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma

Reuters
·
Dec 08

Ash 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody Ibi3003 in Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Dec 08

Hong Kong Stock Short Selling Stats | Dec 8

Stock News
·
Dec 08

Innovent Biologics Wins NRDL Inclusion for Seven Innovative Drugs in China

Reuters
·
Dec 07

Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List

THOMSON REUTERS
·
Dec 07

INNOVENT BIO (01801) Grants 15,000 Share Options and 148,200 Restricted Shares

Stock News
·
Dec 05

Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge

MT Newswires Live
·
Dec 05

Analysis of Hong Kong Stock Connect Holdings | December 5

Stock News
·
Dec 05